-

Alexion to Report Third Quarter 2020 Results on Thursday, October 29, 2020

BOSTON--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the third quarter ended September 30, 2020 before the US financial markets open on October 29, 2020. Following the release of the financial results, Alexion management will conduct a conference call and audio webcast from 8:00-9:00 a.m. Eastern Time (ET).

To participate in this conference call, dial (866) 762-3111 (USA) or (210) 874-7712 (International), conference ID 6582445 shortly before 8:00 a.m. ET. The audio webcast can be accessed on the Investor page of http://ir.alexion.com and an archived version will be available for a limited time following the presentation.

[ALXN-E]

Contacts

Investors
Chris Stevo
Head of Investor Relations
(857) 338-9309

Industry:

Alexion Pharmaceuticals, Inc.

NASDAQ:ALXN
Release Summary
Alexion to Report Third Quarter 2020 Results on Thursday, October 29, 2020
Release Versions
English

Contacts

Investors
Chris Stevo
Head of Investor Relations
(857) 338-9309

More News From Alexion Pharmaceuticals, Inc.

Alexion Announces Positive Topline Results from Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Adults with Generalized Myasthenia Gravis (gMG)

BOSTON--(BUSINESS WIRE)--Alexion Announces Positive Topline Results from Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Adults with Generalized Myasthenia Gravis (gMG)....

Caelum and Alexion Present Additional Phase 2 Data Reinforcing Safety and Tolerability of CAEL-101 in AL Amyloidosis at the European Hematology Association Congress 2021

BORDENTOWN, N.J. & BOSTON--(BUSINESS WIRE)--Caelum and Alexion Present Additional Phase 2 Data Reinforcing Safety and Tolerability of CAEL-101 in AL Amyloidosis at the EHA Congress 2021...

 Alexion Announces FDA Approval of ULTOMIRIS® (ravulizumab-cwvz) for Children and Adolescents with Paroxysmal Nocturnal Hemoglobinuria (PNH)

BOSTON--(BUSINESS WIRE)--Alexion Announces FDA Approval of ULTOMIRIS® (ravulizumab-cwvz) for Children and Adolescents with Paroxysmal Nocturnal Hemoglobinuria (PNH)...
Back to Newsroom